Search - tctmd.com

Displaying 41 - 60 of 95

Sort: Relevancy | Date

News Conference News LINC 2020

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

L.A. McKeown

January 30, 2020

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

L.A. McKeown

January 29, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Daily News

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

L.A. McKeown

January 15, 2020

News Features

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

L.A. McKeown

December 12, 2019

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

L.A. McKeown

November 13, 2019

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Daily News

Endo-First Strategy Matches Surgery in Select CLI Patients: Retrospective Data

Caitlin E. Cox

July 30, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Caitlin E. Cox

January 29, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Industry News

Veryan Medical receives PMA approval for BioMimics 3D

October 05, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

Advertisement

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

Lutonix BTK Studies: Below-the-Knee Challenges Linger

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

Endo-First Strategy Matches Surgery in Select CLI Patients: Retrospective Data

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Veryan Medical receives PMA approval for BioMimics 3D

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content